$2.03
6.02% today
Nasdaq, Apr 03, 06:50 pm CET
ISIN
US09077A1060
Symbol
BMEA
Sector
Industry

Biomea Fusion Inc Stock price

$2.16
-0.48 18.18% 1M
-7.97 78.68% 6M
-1.72 44.33% YTD
-10.64 83.13% 1Y
-2.56 54.24% 3Y
-16.44 88.39% 5Y
-16.44 88.39% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.17 8.54%
ISIN
US09077A1060
Symbol
BMEA
Sector
Industry

Key metrics

Market capitalization $81.16m
Enterprise Value $31.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.50
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-144.07m
Free Cash Flow (TTM) Free Cash Flow $-120.26m
Cash position $58.28m
EPS (TTM) EPS $-3.84
P/E forward negative
Short interest 46.64%
Show more

Is Biomea Fusion Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Biomea Fusion Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Biomea Fusion Inc forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Biomea Fusion Inc forecast:

Buy
71%
Hold
29%

Financial data from Biomea Fusion Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.69 1.69
60% 60%
-
-1.69 -1.69
60% 60%
-
- Selling and Administrative Expenses 23 23
49% 49%
-
- Research and Development Expense 118 118
15% 15%
-
-142 -142
17% 17%
-
- Depreciation and Amortization 1.69 1.69
60% 60%
-
EBIT (Operating Income) EBIT -144 -144
14% 14%
-
Net Profit -138 -138
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biomea Fusion Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomea Fusion Inc Stock News

Neutral
GlobeNewsWire
2 days ago
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of Biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Company's common s...
Neutral
GlobeNewsWire
3 days ago
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, reported fourth quarter and full year 2024 financial results and corporate highlights.
Neutral
GlobeNewsWire
9 days ago
Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role.
More Biomea Fusion Inc News

Company Profile

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Head office United States
CEO Michael Hitchcock
Employees 106
Founded 2017
Website biomeafusion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today